Table 3. Overall seroprevalence of IgG antibodies to SARS-CoV-2 on point-of-care testing by participant characteristics

	Maccura test negative, valid participants, n	Maccura test positive, valid participants, n	Diagreat test negative, valid participants, n	Diagreat test positive, valid participants, n	Seroprevalence estimate via Maccura, %	Seroprevalence estimate via Maccura, 95% CI	Seroprevalence estimate via Diagreat, %	Seroprevalence estimate via Diagreat, 95% CI
Overall	868	99	812	106	12.3	7.4 to 16.0	4.5	0.0 to 14.7
Sex
Female	518	59	484	62	12.3	7.1 to 16.8	4.9	0.0 to 15.9
Male	350	40	328	44	12.3	6.6 to 17.7	4.3	0.0 to 14.8
Age, years
18–34	143	22	118	26	16.8	9.1 to 25.6	1.3	0.0 to 12.8
35–49	212	20	199	20	9.9	3.8 to 16.4	6.0	0.0 to 17.1
50–64	256	43	247	42	18.3	11.8 to 25.0	8.5	0.0 to 20.3
≥65	257	14	248	18	5.0	0.0 to 10.0	0.0	0.0 to 9.2
Participant type
Patient	713	83	674	88	12.6	7.5 to 16.6	4.5	0.0 to 14.8
Healthcare worker	155	16	138	18	11.1	4.2 to 18.6	4.5	0.0 to 17.3
Administration	32	1	31	1	2.5	0.0 to 16.7	0.0	0.0 to 10.6
Nursing	44	7	41	8	17.6	5.9 to 33.8	10.7	0.0 to 30.6
Doctor	36	4	35	4	12.3	1.5 to 29.6	3.0	0.0 to 22.3
Other healthcare staff	43	4	31	5	10.1	0.6 to 24.9	7.7	0.0 to 29.2
History PCR and symptoms
Previous symptoms suggestive of SARS-CoV-2	266^a	73	257	77	28.7	21.7 to 36.0	19.9	0.0 to 32.8
No previous symptoms suggestive of SARS-CoV-2	601^a	26	555	29	3.5	0.0 to 6.9	0.0	0.0 to 5.7
Previous PCR nasopharyngeal swab for SARS-CoV-2	99	39	97	38	38.5	27.7 to 50.6	26.6	0.0 to 43.4
No previous PCR nasopharyngeal swab for SARS-CoV-2	769	60	715	68	8.0	3.1 to 11.5	0.6	0.0 to 10.8

^aOne patient did not have a valid option recorded. PCR = polymerase chain reaction.